Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 287

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Open access
Desai, Akshay S., Webb, David J., Taubel, Jorg, Casey, Sarah, Cheng, Yansong, Robbie, Gabriel J., Foster, Don, Huang, Stephen A., Rhyee, Sean, Sweetser, Marianne T., Bakris, George L.·2023·New England Journal of Medicine

Abstract

BACKGROUND: Angiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis. METHODS: In this phase 1 study, patients with hypertension were randomly assigned in a 2:1 ratio to receive either a single ascending subcutaneous dose of zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg) or placebo and were followed for 24 weeks (Part A). Part B assessed the effect of the 800-mg dose of zilebesiran on blood pressure under low- or high-salt diet conditions, and Part E the effect of that dose when coadministered with irbesartan. End points included safety, pharmacokinetic and pharmacodynamic characteristics, and the change from baseline in systolic and diastolic blood pressure, as measured by 24-hour ambulatory blood-pressure monitoring. RESULTS: Of 107 patients enrolled, 5 had mild, transient injection-site reactions. There were no reports of hypotension, hyperkalemia, or worsening of renal function resulting in medical intervention. In Part A, patients receiving zilebesiran had decreases in serum angiotensinogen levels that were correlated with the administered dose (r = -0.56 at week 8; 95% confidence interval, -0.69 to -0.39). Single doses of zilebesiran (≥200 mg) were associated with decreases in systolic blood pressure (>10 mm Hg) and diastolic blood pressure (>5 mm Hg) by week 8; these changes were consistent throughout the diurnal cycle and were sustained at 24 weeks. Results from Parts B and E were consistent with attenuation of the effect on blood pressure by a high-salt diet and with an augmented effect through coadministration with irbesartan, respectively. CONCLUSIONS: Dose-dependent decreases in serum angiotensinogen levels and 24-hour ambulatory blood pressure were sustained for up to 24 weeks after a single subcutaneous dose of zilebesiran of 200 mg or more; mild injection-site reactions were observed. (Funded by Alnylam Pharmaceuticals; ClinicalTrials.gov number, NCT03934307; EudraCT number, 2019-000129-39.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2208391

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 287

Metadata

Authors
Desai, A. S., Webb, D. J., Taubel, J., Casey, S., Cheng, Y., Robbie, G. J., Foster, D., Huang, S. A., Rhyee, S., Sweetser, M. T., & Bakris, G. L.
Venue
New England Journal of Medicine
Published
2023-07-20
Volume
389
Issue
3
Pages
228-238
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4384817572
Cited by
287
References
21
FWCI
50.48
Type
journal article
Language
en
Open access
green
Funders
Alnylam Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. https://app.cochat.ai/papers/10.1056/nejmoa2208391
The paper
Desai, A. S., Webb, D. J., Taubel, J., Casey, S., Cheng, Y., Robbie, G. J., Foster, D., Huang, S. A., Rhyee, S., Sweetser, M. T., & Bakris, G. L. (2023). Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2208391

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.